Abstract

Background: Administration of smoking cessation medications in anticipation of a nominated quit date can promote abstinence. How this occurs isnot widely understood, but may be due to the disruption of contingencies between smoking behaviour and acute drug effects.Aims: The aim of this study was to explore this relationship, we examined the effect of pre-quit nicotine replacement therapy on susceptibility torelapse in an animal model of nicotine dependence.Methods: Rats were trained to intravenously self-administer nicotine across 20 days. Continuous low-dose nicotine was administered via a miniosmotic pump either across the last 7 days of self-administration and across 6 days of extinction, or across extinction only. Cue- and drug-inducedreinstatements of responding were then measured with mini-pumps retained, the day after mini-pump removal or one week later.Results: Pre-quit nicotine administration markedly reduced self-administration across the last days of training as the response, and its associatedcues, no longer reliably predicted an acute drug effect. Pre-quit, but not post-quit, nicotine administration significantly attenuated cue-inducedreinstatement once mini-pumps were removed, indicating that the contingency disruption across training reduced the conditioned reinforcingproperties of the cue at test. Both pre-quit and post-quit nicotine attenuated nicotine-primed reinstatement.Conclusions: Together these results suggest that administration of a nicotine replacement prior to a nominated quit date may enhance resistance torelapse via disruption of the contingency between a response, its associated cues, and a rewarding nicotine effect.